Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05519839
Registration number
NCT05519839
Ethics application status
Date submitted
26/08/2022
Date registered
29/08/2022
Date last updated
13/05/2024
Titles & IDs
Public title
A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
Query!
Scientific title
A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle and Quadrivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M™ Adjuvant in Healthy Participants = 50 to = 80 Years of Age
Query!
Secondary ID [1]
0
0
2019nCoV-CIC-E-201
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
COVID-19
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
COVID-19
0
0
Query!
Influenza
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - CIC Vaccine
Treatment: Drugs - CIC Vaccine
Treatment: Drugs - qNIV Vaccine
Treatment: Drugs - SARS-CoV-2 rS Vaccine
Treatment: Drugs - Influenza Vaccine
Treatment: Drugs - CIC Vaccine
Experimental: Group A (Part 1) - CIC Vaccine Formulation 1 doses of Formulation 1. 1 dose on Days 0.
Experimental: Group B (Part 1) - CIC Vaccine Formulation 1 doses of Formulation 2. 1 dose on Days 0.
Experimental: Group C (Part 1) - CIC Vaccine Formulation 1 doses of Formulation 3. 1 dose on Days 0.
Experimental: Group D (Part 1) - CIC Vaccine Formulation1 doses of Formulation 4. 1 dose on Days 0.
Experimental: Group E (Part 1) - CIC Vaccine Formulation 1 doses of Formulation 5. 1 dose on Days 0.
Experimental: Group F (Part 1) - CIC Vaccine Formulation 1 doses of Formulation 6. 1 dose on Days 0.
Experimental: Group G (Part 1) - CIC Vaccine Formulation 1 doses of Formulation 7. 1 dose on Days 0.
Experimental: Group H (Part 1) - CIC Vaccine Formulation 1 doses of Formulation 8. 1 dose on Days 0.
Experimental: Group I (Part 1) - CIC Vaccine Formulation 1 doses of Formulation 9. 1 dose on Days 0.
Experimental: Group J (Part 1) - CIC Vaccine Formulation 1 doses of Formulation 10. 1 dose on Days 0.
Experimental: Group K (Part 1) - CIC Vaccine Formulation 1 doses of Formulation 11. 1 dose on Days 0.
Experimental: Group L (Part 1) - qNIV Vaccine Formulation 1 doses of Formulation 12. 1 dose on Days 0.
Experimental: Group M (Part 1) - qNIV Vaccine Formulation 1 doses of Formulation 13. 1 dose on Days 0.
Experimental: Group N (Part 1) - CIC Vaccine Formulation 1 doses of Formulation 14. 1 dose on Days 0.
Experimental: Group O (Part 1) - SARS-CoV-2 rS Vaccine Formulation 1 doses of Formulation 15. 1 dose on Days 0.
Experimental: Group P (Part 1) - Reference Vaccine Formulation 1 doses of Formulation 16. 1 dose on Days 0.
Experimental: Group Q (Part 1) - Reference Vaccine Formulation 1 doses of Formulation 17. 1 dose on Days 0.
Experimental: Group R (Part 1) - Reference Vaccine Formulation 1 doses of Formulation 18. 1 dose on Days 0.
Experimental: Group S (Part 1) - Comparator Influenza Vaccine Formulation 1 doses of Formulation 19. 1 dose on Days 0.
Experimental: Group T (Part 1) - Comparator Influenza Vaccine Formulation 1 doses of Formulation 20. 1 dose on Days 0.
Experimental: Group U (Part 2) - CIC Vaccine Formulation 1 doses of Formulation 1. 1 dose on Days 0.
Experimental: Group V (Part 2) - CIC Vaccine Formulation 1 doses of Formulation 2. 1 dose on Days 0.
Treatment: Drugs: CIC Vaccine
Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV, SARS-CoV-2 rS, and 50 µg Matrix-M1 Adjuvant (CIC Vaccine) on Day 0.
Treatment: Drugs: CIC Vaccine
Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV, SARS-CoV-2 rS, and 75 µg Matrix-M1 Adjuvant (CIC Vaccine) on Day 0.
Treatment: Drugs: qNIV Vaccine
Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV and 75 µg Matrix-M1 Adjuvant (Influenza Vaccine) on Day 0.
Treatment: Drugs: SARS-CoV-2 rS Vaccine
Intramuscular (deltoid) injections of in-clinic mix of various doses of SARS-CoV-2 rS, Diluent, and 50 µg Matrix-M1 Adjuvant (SARS-CoV-2 rS Vaccine) on Day 0.
Treatment: Drugs: Influenza Vaccine
Intramuscular (deltoid) injections of Comparator influenza on Day 0.
Treatment: Drugs: CIC Vaccine
Intramuscular (deltoid) injections of co-formulated mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 µg Matrix-M1 Adjuvant (CIC Vaccine) on Day 0.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Part 1 and Part 2 : Number of participants with solicited local and systemic Adverse Events (AEs)
Query!
Assessment method [1]
0
0
Numbers of participants with solicited local and systemic AEs over the 7 days post-vaccination.
Query!
Timepoint [1]
0
0
Day 0 to Day 7
Query!
Primary outcome [2]
0
0
Part 1 and Part 2 : Percentage of participants with all AEs
Query!
Assessment method [2]
0
0
Proportions of participants reporting all AEs, solicited and unsolicited, over 21 days post-vaccination.
Query!
Timepoint [2]
0
0
Day 0 to Day 21
Query!
Primary outcome [3]
0
0
Part 1 and Part 2 : Percentage of participants with Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)
Query!
Assessment method [3]
0
0
Proportions of participants with MAAEs, AESIs (including PIMMCs and myocarditis and/or pericarditis), SAEs, will be collected for 6 months (approximately 182 days) post-vaccination
Query!
Timepoint [3]
0
0
Day 0 to Day 182
Query!
Secondary outcome [1]
0
0
Part 1 and Part 2 : Hemagglutination Inhibition (HAI) Titers Specific for Vaccine Homologous A and B Influenza Strain(s) and Antigenically Drifted Influenza Strains Expressed as Geometric Mean Titer (GMT)
Query!
Assessment method [1]
0
0
HAI antibody titers specific for the HA receptor binding domains of vaccine-homologous A and B strain(s), and antigenically drifted influenza strains. Derived/calculated endpoints based on GMT, defined as the antilog of the mean of the log-transformed HAI titers on Days 0, 7, 21, 84, and other follow-up time points
Query!
Timepoint [1]
0
0
Day 0 to Day 84
Query!
Secondary outcome [2]
0
0
Part 1 and Part 2 : Hemagglutination Inhibition (HAI) Titers Specific for Vaccine Homologous A and B Influenza Strain(s) and Antigenically Drifted Influenza Strains Expressed as Geometric Mean Fold Rise (GMFR)
Query!
Assessment method [2]
0
0
HAI antibody titers specific for the HA receptor binding domains of vaccine-homologous A and B strain(s), and antigenically drifted influenza strains. Derived/calculated endpoints based on Geometric mean fold rise (GMFRPost/Pre) - defined as the within group ratio of post-vaccination to pre-vaccination (Day 0) HAI GMTs within the same vaccine group on Days 7, 21, 84, and other follow-up time points.
Query!
Timepoint [2]
0
0
Day 0 to Day 84
Query!
Secondary outcome [3]
0
0
Part 1 and Part 2 : Hemagglutination Inhibition (HAI) Titers Specific for Vaccine Homologous A and B Influenza Strain(s) and Antigenically Drifted Influenza Strains Expressed as Seroconversion Rate (SCR)
Query!
Assessment method [3]
0
0
HAI antibody titers specific for the HA receptor binding domains of vaccine-homologous A and B strain(s), and antigenically drifted influenza strains. Derived/calculated endpoints based on Seroconversion rate (SCR) - defined as proportion of participants in a given Vaccine Group with either a baseline reciprocal (Day 0) titer of < 10 and a post-vaccination reciprocal titer = 40, or a baseline reciprocal (Day 0) titer of = 10 and a post-vaccination titer = 4-fold higher than the baseline titer as measured on Days 7, 21, 84, and other follow-up time points
Query!
Timepoint [3]
0
0
Day 0 to Day 84
Query!
Secondary outcome [4]
0
0
Part 1 and Part 2 : Hemagglutination Inhibition (HAI) Titers Specific for Vaccine Homologous A and B Influenza Strain(s) and Antigenically Drifted Influenza Strains Expressed as Seroprotection Rate (SPR)
Query!
Assessment method [4]
0
0
HAI antibody titers specific for the HA receptor binding domains of vaccine-homologous A and B strain(s), and antigenically drifted influenza strains. Derived/calculated endpoints based on Seroprotection rate (SPR) - defined as the proportion of participants with a reciprocal HAI titer = 40 on Days 7, 21, 84, and other follow-up time points.
Query!
Timepoint [4]
0
0
Day 0 to Day 84
Query!
Secondary outcome [5]
0
0
Part 1 and Part 2 : Hemagglutination Inhibition (HAI) Titers Specific for Vaccine Homologous A and B Influenza Strain(s) and Antigenically Drifted Influenza Strains Expressed as Geometric Mean Titer Ratio (GMTR)
Query!
Assessment method [5]
0
0
HAI antibody titers specific for the HA receptor binding domains of vaccine-homologous A and B strain(s), and antigenically drifted influenza strains. Derived/calculated endpoints based on GMTR between select treatment arms at Days 7, 21, 84, and other follow-up time points post-vaccination (adjusted for intergroup variation in baseline [pre-vaccination] titers).
Query!
Timepoint [5]
0
0
Day 0 to Day 84
Query!
Secondary outcome [6]
0
0
Part 1 and Part 2: Neutralizing Antibody Titers Specific for Vaccine Homologous A and B Influenza Strain(s) and/or Antigenically Drifted Influenza Strains Expressed as GMTs
Query!
Assessment method [6]
0
0
Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type A and B strain(s) and/or antigenically drifted influenza strains, as measured by a MN assay expressed as GMTs.
Query!
Timepoint [6]
0
0
Day 0 to Day 84
Query!
Secondary outcome [7]
0
0
Part 1 and Part 2 : Neutralizing Antibody Titers Specific for Vaccine Homologous A and B Influenza Strain(s) and/or Antigenically Drifted Influenza Strains Expressed as GMFR
Query!
Assessment method [7]
0
0
Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type A and B strain(s) and/or antigenically drifted influenza strains, as measured by a MN assay expressed as GMFR
Query!
Timepoint [7]
0
0
Day 0 to Day 84
Query!
Secondary outcome [8]
0
0
Part 1 and Part 2: Neutralizing Antibody Titers Specific for Vaccine Homologous A and B Influenza Strain(s) and/or Antigenically Drifted Influenza Strains Expressed as SCR
Query!
Assessment method [8]
0
0
Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type A and B strain(s) and/or antigenically drifted influenza strains, as measured by a MN assay expressed as SCR.
Query!
Timepoint [8]
0
0
Day 0 to Day 84
Query!
Secondary outcome [9]
0
0
Part 1 and Part 2: Neutralizing Antibody Titers Specific for Vaccine Homologous A and B Influenza Strain(s) and/or Antigenically Drifted Influenza Strains Expressed as GMTR
Query!
Assessment method [9]
0
0
Microneutralization (MN50) antibody responses: neutralizing antibody titers specific to vaccine homologous wild-type A and B strain(s) and/or antigenically drifted influenza strains, as measured by a MN assay expressed as GMTR.
Query!
Timepoint [9]
0
0
Day 0 to Day 84
Query!
Secondary outcome [10]
0
0
Part 1 and Part 2: Serum Immunoglobulin G (IgG) to the SARS-CoV-2 spike protein expressed as GMEU
Query!
Assessment method [10]
0
0
IgG geometric mean enzyme-linked immunosorbent assay (ELISA) unit (GMEU) concentrations (EU/mL) to the SARS-CoV-2 S protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 7, 21, 84, and other follow-up time points, expressed as GMEU.
Query!
Timepoint [10]
0
0
Day 0 to Day 84
Query!
Secondary outcome [11]
0
0
Part 1 and Part 2: Serum IgG to the SARS-CoV-2 spike protein expressed as GMFR
Query!
Assessment method [11]
0
0
IgG geometric mean enzyme-linked immunosorbent assay (ELISA) unit (GMEU) concentrations (EU/mL) to the SARS-CoV-2 S protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 7, 21, 84, and other follow-up time points, expressed as GMFR.
Query!
Timepoint [11]
0
0
Day 0 to Day 84
Query!
Secondary outcome [12]
0
0
Part 1 and Part 2: Serum IgG to the SARS-CoV-2 spike protein expressed as SCR
Query!
Assessment method [12]
0
0
IgG geometric mean enzyme-linked immunosorbent assay (ELISA) unit (GMEU) concentrations (EU/mL) to the SARS-CoV-2 S protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 7, 21, 84, and other follow-up time points expressed as SCR.
Query!
Timepoint [12]
0
0
Day 0 to Day 84
Query!
Secondary outcome [13]
0
0
Part 1 and Part 2: Serum IgG to the SARS-CoV-2 spike protein expressed as Geometric Mean ELISA Unit Ratio (GMEUR)
Query!
Assessment method [13]
0
0
IgG geometric mean enzyme-linked immunosorbent assay (ELISA) unit (GMEU) concentrations (EU/mL) to the SARS-CoV-2 S protein from the matched vaccine construct (and mismatched variant if available), at Days 0, 7, 21, 84, and other follow-up time points, expressed as GMEUR.
Query!
Timepoint [13]
0
0
Day 0 to Day 84
Query!
Secondary outcome [14]
0
0
Part 1 and Part 2: Microneutralization assay (MN) 50 GMTs to the SARS-CoV-2 expressed as GMTs
Query!
Assessment method [14]
0
0
MN50 GMTs to the SARS-CoV-2 from the matched vaccine construct (and mismatched variant if available), at Days 0, 7, 21, 84, and other follow-up time points, expressed as GMTs.
Query!
Timepoint [14]
0
0
Day 0 to Day 84
Query!
Secondary outcome [15]
0
0
Part 1 and Part 2: MN50 GMTs to the SARS-CoV-2 expressed as GMFR
Query!
Assessment method [15]
0
0
MN50 GMTs to the SARS-CoV-2 from the matched vaccine construct (and mismatched variant if available), at Days 0, 7, 21, 84, and other follow-up time points expressed as GMFR.
Query!
Timepoint [15]
0
0
Day 0 to Day 84
Query!
Secondary outcome [16]
0
0
Part 1 and Part 2: MN50 GMTs to the SARS-CoV-2 expressed as SCR
Query!
Assessment method [16]
0
0
MN50 GMTs to the SARS-CoV-2 from the matched vaccine construct (and mismatched variant if available), at Days 0, 7, 21, 84, and other follow-up time points expressed as SCR.
Query!
Timepoint [16]
0
0
Day 0 to Day 84
Query!
Secondary outcome [17]
0
0
Part 1 and Part 2: MN50 GMTs to the SARS-CoV-2 expressed as GMTR
Query!
Assessment method [17]
0
0
MN50 GMTs to the SARS-CoV-2 from the matched vaccine construct (and mismatched variant if available), at Days 0, 7, 21, 84, and other follow-up time points expressed as GMTR
Query!
Timepoint [17]
0
0
Day 0 to Day 84
Query!
Eligibility
Key inclusion criteria
To be included in this study, each individual must satisfy all the following criteria:
1. Medically stable adult male or females = 50 to = 80 years of age at screening.
2. Participants may have 1 or more chronic medical diagnoses, but should be clinically
stable as assessed by:
1. Absence of changes in medical therapy in the past 2 months due to treatment
failure or toxicity;
2. Absence of medical events qualifying as SAEs within 3 months; and
3. Absence of known, current, and life-limiting diagnoses which render survival to
completion of the protocol unlikely in the opinion of the investigator.
3. The participant has a body mass index (BMI) of 17 to 40 kg/m2, inclusive, at
screening.
4. Willing and able to give informed consent prior to study enrollment.
5. Able to attend study visits, comply with study requirements, and provide reliable and
complete reports of AEs.
6. Participants must have completed a primary vaccination series against SARS-CoV-2 with
an authorized COVID 19 vaccine (and fulfill national recommendations for his/her age
and morbidity category) with receipt of second/last dose of authorized vaccine (with
or without boosters[s]) = 8 weeks prior to enrollment (first study vaccination).
7. Women of childbearing potential (defined as any female participant who is NOT
surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral
oophorectomy] or postmenopausal [defined as amenorrhea at least 12 consecutive
months]) must agree to be heterosexually inactive from at least 28 days prior to
enrollment and through the end of the study OR agree to consistently use a medically
acceptable method of contraception listed below from at least 28 days prior to
enrollment and through the end of the study
1. Condoms (male or female) with spermicide (if acceptable in country)
2. Diaphragm with spermicide
3. Cervical cap with spermicide
4. Intrauterine device
5. Oral or patch contraceptives
6. Norplant®, Depo-Provera®, or other in-country regulatory approved contraceptive
method that is designed to protect against pregnancy
7. Abstinence, as a form of contraception, is acceptable if in line with the
participant's lifestyle
8. Participants must be healthy and medically stable, as determined by the investigator
(based on review of health status, vital signs [to include body temperature], medical
history, and targeted physical examination [to include body weight]). Vital signs must
be within medically acceptable ranges prior to vaccination.
9. Participants must agree to not participate in any other SARS-CoV-2 or influenza
prevention or treatment studies for the duration of the study. Note: For participants
who become hospitalized with COVID-19, participation in investigational treatment
studies is permitted.
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
If an individual meets any of the following criteria, he or she is ineligible for this
study:
1. History of laboratory-confirmed (by Polymerase Chain Reaction (PCR) or rapid antigen
test) COVID-19 or asymptomatic SARS-CoV-2 infection = 8 weeks prior to enrollment.
(NOTE: Symptomatic COVID-19 or asymptomatic SARS-CoV-2 infection > 8 weeks prior to
enrollment is NOT exclusionary)
2. Any ongoing, symptomatic acute illness requiring medical or surgical care or chronic
illness that required changes in medication in the past 2 months indicating that
chronic illness/disease is not stable (at the discretion of the investigator). This
includes any current workup of undiagnosed illness that could lead to a new condition.
3. Serious chronic diseases inclusive of:
1. Uncontrolled hypertension (NOTE: well controlled hypertension = grade 2 in NOT
exclusionary);
2. Congestive heart failure with a history of an acute exacerbation of any severity
in the prior 2 years (NOTE:
mild well-controlled congestive heart failure is NOT exclusionary);
3. Chronic obstructive pulmonary disease (COPD) with a history of an acute
exacerbation of any severity in the prior 2 years (NOTE: mild well-controlled
COPD is NOT exclusionary);
4. In the past 3 months, evidence of unstable coronary artery disease as manifested
by cardiac interventions (eg, cardiac stent placement, coronary artery bypass
grafting [CABG]) surgery, new cardiac medications for control of symptoms, or
unstable angina (NOTE: stable coronary heart disease is NOT exclusionary);
5. Asthma with a history of exacerbation in the prior 2 years or worsening of asthma
symptoms or requiring changes in asthma control medications in the past 2 months
(NOTE: well-controlled asthma is NOT exclusionary).
6. Type 1 or type 2 diabetes (adult onset) requiring insulin (NOTE: non-insulin
dependent type 2 diabetes is NOT exclusionary);
7. Chronic kidney disease/renal insufficiency;
8. Chronic gastrointestinal and hepatic diseases; or
9. Chronic neurological diseases (such as multiple sclerosis, dementia, Parkinson's
disease, degenerative neurological conditions, neuropathy, or epilepsy), history
of stroke within 12 months with residual symptoms, or previous neurological
disorder within 12 months with residual symptoms (NOTE: history of migraine or
chronic headaches or nerve root compression that have been stable on treatment
for the last 4 weeks are NOT exclusionary).
4. Participation in research involving an investigational product (drug/biologic/device)
within 90 days before planned date of vaccination.
5. Use of COVID-19 prophylactic or treatment monoclonal antibodies or antibody cocktails
within 90 days prior to planned date of vaccination.
6. History of a serious reaction to prior influenza vaccination or known allergy to
constituents of influenza vaccines - including egg proteins - or polysorbate 80; or
any known allergies to products contained in the investigational product.
7. Any history of anaphylaxis to any prior vaccine.
8. History of Guillain-Barré Syndrome within 6 weeks following a previous influenza
vaccine.
9. Receipt of any vaccine in the 4 weeks preceding the study vaccination and any
influenza vaccine within 8 weeks preceding the study vaccination. Note: Routine
vaccinations will not be allowed until after study Day 21 and COVID and influenza
vaccination will not be allowed until after Day 84.
10. Any known or suspected autoimmune or immunosuppressive illness, congenital or
acquired, based on medical history and/or physical examination (NOTE: mild psoriasis
is not exclusionary).
11. Chronic administration (defined as more than 14 continuous days) of immunosuppressants
or other immune- modifying drugs within 6 months prior to the administration of the
study vaccines. An immunosuppressant dose of glucocorticoid is defined as a systemic
dose = 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and
nasal glucocorticoids is permitted.
12. Administration of immunoglobulins and/or any blood products within the 3 months
preceding the administration of the study vaccine or during the study.
13. Active cancer (malignancy) therapy within 3 years prior to study vaccination (with the
exception of adequately treated non-melanomatous skin carcinoma or lentigo maligna and
uterine cervical carcinoma in situ without evidence of disease, at the discretion of
the investigator).
14. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to
the end of study (EoS).
15. Known disturbance of coagulation.
16. Suspected or known history of alcohol abuse or drug addiction within 2 years prior to
study vaccination, which in the opinion of the investigator, might interfere with
protocol compliance.
17. Acute disease at the time of enrollment (defined as the presence of a moderate or
severe illness with or without fever, or an oral temperature > 38.0°C, on the planned
day of vaccine administration).
18. History of myocarditis or pericarditis.
19. Any condition that in the opinion of the investigator would pose a health risk to the
participant if enrolled or could interfere with evaluation of the vaccine or
interpretation of study results (including neurologic or psychiatric conditions deemed
likely to impair the quality of safety reporting).
20. Study team member or immediate family member of any study team member (inclusive of
Sponsor, Contract Research Organization, and study site personnel involved in the
conduct or planning of the study.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/12/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
24/12/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1579
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,New South WhalesNorther TerritoryQLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Paratus Clinical Research - Canberra - Bruce
Query!
Recruitment hospital [2]
0
0
Paratus Clinical Research - Western Sydney - Blacktown
Query!
Recruitment hospital [3]
0
0
Emeritus Research - Sydney - Botany
Query!
Recruitment hospital [4]
0
0
Genesis Central Coast - Broadmeadow
Query!
Recruitment hospital [5]
0
0
Northern Beaches Clinical Research - Brookvale
Query!
Recruitment hospital [6]
0
0
East Sydney Doctors - Darlinghurst
Query!
Recruitment hospital [7]
0
0
Holdsworth House Medical Brisbane - Darlinghurst
Query!
Recruitment hospital [8]
0
0
Oztrials Clinical Research - Drummoyne
Query!
Recruitment hospital [9]
0
0
Paratus Clinical Research - Central Coast - Kanwal
Query!
Recruitment hospital [10]
0
0
Australian Clinical Research Network - Maroubra
Query!
Recruitment hospital [11]
0
0
Hunter Diabetes Centre - Merewether
Query!
Recruitment hospital [12]
0
0
Sutherland Clinical Trials - Miranda
Query!
Recruitment hospital [13]
0
0
Illawarra Health and Medical Research Institute - Wollongong
Query!
Recruitment hospital [14]
0
0
Northside Health - Coffs Harbour
Query!
Recruitment hospital [15]
0
0
Novatrials - Kotara
Query!
Recruitment hospital [16]
0
0
Menzies Darwin - Tiwi
Query!
Recruitment hospital [17]
0
0
Paratus Clinical Research - Brisbane Clinic - Albion
Query!
Recruitment hospital [18]
0
0
Mater Adult Hospital - Brisbane
Query!
Recruitment hospital [19]
0
0
Nucleus Network Pty Ltd - Herston
Query!
Recruitment hospital [20]
0
0
Core Research Group - Milton
Query!
Recruitment hospital [21]
0
0
Austrials Pty Ltd - Taringa - Taringa
Query!
Recruitment hospital [22]
0
0
AusTrials (Wellers Hill) - Tarragindi
Query!
Recruitment hospital [23]
0
0
CMAX - Adelaide
Query!
Recruitment hospital [24]
0
0
Emeritus Research - Camberwell
Query!
Recruitment hospital [25]
0
0
Nucleus Network Limited - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Bruce
Query!
Recruitment postcode(s) [2]
0
0
2148 - Blacktown
Query!
Recruitment postcode(s) [3]
0
0
- Botany
Query!
Recruitment postcode(s) [4]
0
0
- Broadmeadow
Query!
Recruitment postcode(s) [5]
0
0
- Brookvale
Query!
Recruitment postcode(s) [6]
0
0
- Darlinghurst
Query!
Recruitment postcode(s) [7]
0
0
- Drummoyne
Query!
Recruitment postcode(s) [8]
0
0
- Kanwal
Query!
Recruitment postcode(s) [9]
0
0
- Maroubra
Query!
Recruitment postcode(s) [10]
0
0
- Merewether
Query!
Recruitment postcode(s) [11]
0
0
- Miranda
Query!
Recruitment postcode(s) [12]
0
0
- Wollongong
Query!
Recruitment postcode(s) [13]
0
0
2450 - Coffs Harbour
Query!
Recruitment postcode(s) [14]
0
0
2289 - Kotara
Query!
Recruitment postcode(s) [15]
0
0
- Tiwi
Query!
Recruitment postcode(s) [16]
0
0
- Albion
Query!
Recruitment postcode(s) [17]
0
0
- Brisbane
Query!
Recruitment postcode(s) [18]
0
0
- Herston
Query!
Recruitment postcode(s) [19]
0
0
- Milton
Query!
Recruitment postcode(s) [20]
0
0
- Taringa
Query!
Recruitment postcode(s) [21]
0
0
- Tarragindi
Query!
Recruitment postcode(s) [22]
0
0
- Adelaide
Query!
Recruitment postcode(s) [23]
0
0
- Camberwell
Query!
Recruitment postcode(s) [24]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
New Zealand
Query!
State/province [1]
0
0
Hawkes Bay
Query!
Country [2]
0
0
New Zealand
Query!
State/province [2]
0
0
Manawatu-Wanganui
Query!
Country [3]
0
0
New Zealand
Query!
State/province [3]
0
0
Wellington
Query!
Country [4]
0
0
New Zealand
Query!
State/province [4]
0
0
Auckland
Query!
Country [5]
0
0
New Zealand
Query!
State/province [5]
0
0
Christchurch
Query!
Country [6]
0
0
New Zealand
Query!
State/province [6]
0
0
Dunedin
Query!
Country [7]
0
0
New Zealand
Query!
State/province [7]
0
0
Tauranga
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novavax
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a randomized, observer-blinded, Phase 2 study evaluating the safety and
immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARSCoV2) recombinant
spike (rS) (SARS-CoV-2 rS) nanoparticle and quadrivalent hemagglutinin (HA) nanoparticle
influenza vaccine (qNIV) combination vaccine with Matrix-M™ adjuvant; this combination
vaccine.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05519839
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Development
Query!
Address
0
0
Novavax, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05519839
Download to PDF